NCT00406744

Efficacy of Retreatments With Intravitreal Bevacizumab

Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Asociación para Evitar la Ceguera en México · Academic / Other
• Sex: All
• Age: 60 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Conditions

• Age Related Macular Degeneration
• Choroidal Neovascularization

Interventions

Type	Name	Description
DRUG	Intravitreal injection of Bevacizumab

Timeline

• Start date: 2006-05-01
• Primary completion: 2006-05-01
• Completion: 2006-11-01
• First posted: 2006-12-04
• Last updated: 2024-06-03

Locations

1 site across 1 country: Mexico